descriptionPublicationkeyboard_double_arrow_right Article 18 Sep 2020 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Transplantation, volume 104, pages 1,972-1,973 (issn: 0041-1337,

Authors: Maeve, O'Reilly; Karl S, Peggs;

doi: 10.1097/tp.0000000000003283

pmid: 32969986

Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD

- Summary
- Subjects
- Related research
  (1)
- Metrics

tips_and_updates
Recommended

Related Organizations

University College London
United Kingdom

Keywords

Epstein-Barr Virus Infections, Herpesvirus 4, Human, Lymphoma, Humans, Immunotherapy, Rituximab, Lymphoproliferative Disorders

1 Research products, page 1 of 1

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
2020IsAmongTopNSimilarDocuments

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average

Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD

Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD

1 Research products, page 1 of 1

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation